真实世界结缔组织病队列的临床试验合格性:LEAP队列结果
该研究系统回顾已发表结缔组织病(CTD)III期试验,并将最常用分类标准应用于多中心非选择性真实世界CTD队列,评估其代表性。共识别42项CTD试验,391例真实世界患者中仅187/391(47.8%)符合最严格试验合格标准。
要点
- 42项CTD III期试验中无混合性结缔组织病(MCTD)或未分化结缔组织病(UCTD)试验。
- 391例真实世界CTD患者中仅187/391(47.8%)符合最严格试验合格标准。
- 211/300(70.3%)原发性干燥综合征、SLE、系统性硬化或特发性炎性肌病患者符合相应分类标准。
核心结论
- 在非选择性真实世界CTD队列中,多达一半患者因不符合分类标准、存在重叠特征或其主要疾病缺乏试验而无法参加临床试验。
- 为解决新疗法可及性不平等,临床试验设计应改进CTD的合格标准。
研究设计与样本
- 研究系统回顾了clinicaltrials.gov上所有已发表的主要CTD III期试验,并将临床试验中最常用的分类标准应用于多中心非选择性CTD队列。
- 共识别42项CTD III期试验,真实世界CTD队列纳入391例患者。
主要发现
- 42项CTD试验中,38项(90%)要求患者符合相应疾病的分类标准。
- 8项(19.0%)排除重叠CTD患者,另2项(4.8%)排除特定重叠特征如肺动脉高压;1项研究明确允许重叠综合征。
- 真实世界队列中,UCTD或MCTD患者91/391(23.3%)因无合格诊断而被排除在临床试验之外。
- 原发性干燥综合征、SLE、系统性硬化或特发性炎性肌病患者中,211/300(70.3%)符合相应诊断分类标准,其中24/211(11.4%)符合一种以上CTD标准。
- 基于医师诊断和最严格试验合格标准,共187/391(47.8%)患者符合招募条件。
关键数值与推荐
- 42项CTD试验中38项(90%)要求符合相应疾病分类标准。
- 8项(19.0%)排除重叠CTD,2项(4.8%)排除特定重叠特征,1项明确允许重叠综合征。
- UCTD或MCTD患者91/391(23.3%)因无合格诊断被排除。
- 原发性干燥综合征、SLE、系统性硬化或特发性炎性肌病患者中211/300(70.3%)符合分类标准,24/211(11.4%)符合一种以上CTD标准。
- 187/391(47.8%)患者符合最严格试验合格标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Classification criteria aim to identify a homogenous population of patients for research. We aimed to quantify how well phase-III trials in connective tissue diseases (CTDs) represent a real-world cohort. METHODS: A comprehensive review of all major published phase-III trials in CTDs was performed (clinicaltrials.gov). Classification criteria utilised most commonly in clinical trials were applied to a multicentre unselected CTD cohort. RESULTS: There were 42 CTD trials identified, with no trials in mixed (MCTD) or undifferentiated CTD (UCTD). The majority of trials (N = 38, 90 %) required patients to meet classification criteria for their respective disease. Eight (19.0 %) excluded patients with overlapping CTDs and a further two (4.8 %) excluded specific overlapping features, such as pulmonary arterial hypertension. One study explicitly allowed overlap syndromes. Our real-world CTD cohort included 391 patients. Patients with UCTD or MCTD (91/391, 23.3 %) would be excluded from participation in clinical trials for not having an eligible diagnosis. Of patients with primary Sjögren's syndrome (pSS), SLE, systemic sclerosis (SSc) or idiopathic inflammatory myopathy (IIM), 211/300 (70.3 %) met the classification criteria for their respective diagnosis and 24/211 (11.4 %) met criteria for >1 CTD. In total, 187/391 (47.8 %) would be eligible for recruitment, based upon their physician diagnosis, and most stringent trial eligibility criteria. CONCLUSION: In an unselected, real-world CTD cohort, up to half of patients are ineligible for clinical trials due to not meeting classification criteria, overlapping features or a lack of trials within their primary disease. To address this inequality in access to novel therapies, clinical trial design should evolve eligibility criteria in CTDs.
引用
- Dyball S, Madenidou AV, Rodziewicz M, et al. Clinical trial eligibility of a real-world connective tissue disease cohort: Results from the LEAP cohort. Semin Arthritis Rheum. 2024. PMID: 38796923. doi:10.1016/j.semarthrit.2024.152463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。